Nanobiotix S.A. (NBTX)
Healthcare • Biotechnology
StockNasdaqGSFranceUS63009J1079
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Nanobiotix S.A., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 15:26. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 30 Mar 2027 17:00 | — | — | — | Upcoming |
| 07 Apr 2022 20:00 | -1.06 | -0.20 | +81.2% | Beat |
Annual results · EUR
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 29.6M | +355.3% | -24M | -80.8% | -0.50 | +65.3% | -34M |
| 2024 | -11.6M | -138.6% | -68.1M | 586.8% | -1.44 | -33.3% | -20.4M |
| 2023 | 30.1M | — | -39.7M | -132.1% | -1.08 | +34.1% | -12.8M |
| 2022 | 0 | — | -57M | — | -1.64 | — | -37.2M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 30.39 | 33.35 | 27.49 | 30.44 | -2.96% | 1,694,186 | |
| Oct 2026 | 29.99 | 34.76 | 20.70 | 31.37 | +0.67% | 3,112,000 | |
| Sep 2026 | 39.28 | 43.40 | 31.07 | 31.16 | -23.33% | 2,824,100 | |
| Aug 2026 | 37.57 | 46.69 | 35.41 | 40.64 | +5.87% | 3,620,700 | |
| Jul 2026 | 37.40 | 42.92 | 35.00 | 38.38 | +1.82% | 2,754,100 | |
| Jun 2026 | 38.94 | 40.01 | 31.68 | 37.70 | -6.68% | 1,603,500 | |
| May 2026 | 34.99 | 57.14 | 30.30 | 40.40 | +16.70% | 1,812,500 | |
| Apr 2026 | 32.90 | 34.78 | 29.01 | 34.62 | +12.15% | 1,563,100 | |
| Mar 2026 | 32.71 | 41.89 | 28.40 | 30.87 | -0.55% | 1,547,800 | |
| Feb 2026 | 20.99 | 31.62 | 20.71 | 31.04 | +47.81% | 600,800 | |
| 51 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Nanobiotix to Participate in Investor Conferences in November (opens in a new tab) 09 Nov 2026 21:15
- Nanobiotix (ENXTPA:NANO) Could Be 46% Undervalued As Melanoma Trial Results Land (opens in a new tab) Simply Wall St. · 26 Oct 2026 23:31
- Nanobiotix stock gains on positive melanoma trial data (opens in a new tab) Investing.com · 26 Oct 2026 15:35
- Nanobiotix (ENXTPA:NANO) Could Be 59% Undervalued After Its CFO Change (opens in a new tab) Simply Wall St. · 10 Oct 2026 18:11
- Can J&J’s Partnership Drive More Upside for Nanobiotix? (opens in a new tab) Insider Monkey · 28 Sep 2026 20:31
- Nanobiotix (NBTX): Can Lung Tumor Control Justify Repeat Radiation Risks? (opens in a new tab) Insider Monkey · 17 Sep 2026 18:06
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 32.25 USD
- Market cap
- 1.6B
- Exchange
- NasdaqGS
- Country
- France
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 0.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 | — |
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 1.7 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 0.0 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
- Thin interest cover: operating profit is only -1.0× the interest
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 12 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | -192.28× | Weak | 14.16× |
| Price / book | -43.69× | Weak | 3.5× |
| Price / sales | 142.79× | Weak | 3.33× |
| EV / EBITDA | -56.06× | Weak | 11.19× |
| Free cash flow yield | -2% | Weak | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 100% | Good | 54.9% |
| Operating margin | -257.4% | Weak | 5.8% |
| Net margin | 0% | Weak | 1.2% |
| Return on assets | -21.3% | Weak | 2.7% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | -0.7% | Weak | 10.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | -1.13× | Good | 0.4× |
| Interest cover | -1.04× | Weak | 2.17× |
| Current ratio | 1.44× | Fair | 2.64× |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow NBTX and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.